SCHEMBL1364647

SCHEMBL1364647

CCCCCCCCCCCCCCCCCCCCCc1c(C(=O)OCC)sc2c1sc1c3sc(C(=O)OCC)c(CCCCCCCCCCCCCCCCCCCCC)c3sc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 5/20 0.49
L3MBTL1 Q9Y468 1/20 0.45
NPSR1 Q6W5P4 1/20 0.42
TSHR P16473 1/20 0.40
MAPT P10636 2/20 0.40
KMT2A Q03164 2/20 0.40
GAA P10253 1/20 0.40
HSD17B10 Q99714 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
MC4R P32245 1/20 0.40
ALDH1A1 P00352 3/20 0.39
HPGD P15428 1/20 0.39
CYP1A2 P05177 1/20 0.39
GSK3B P49841 1/20 0.38
CYP2C9 P11712 1/20 0.38
PLA2G4A P47712 1/20 0.38
AKT1 P31749 1/20 0.38
IRS1 P35568 1/20 0.38
GAB1 Q13480 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1157118 1.00 GPR35 (0.49) GPR35L3MBTL1NPSR1TSHRMAPT
SCHEMBL1157064 1.00 GPR35 (0.49) GPR35L3MBTL1NPSR1TSHRMAPT
SCHEMBL1365121 1.00 GPR35 (0.49) GPR35L3MBTL1NPSR1TSHRMAPT
SCHEMBL13961926 0.88 GPR35 (0.65) GPR35L3MBTL1NPSR1TSHRMAPT
SCHEMBL9948709 0.88 GPR35 (0.49) GPR35L3MBTL1NPSR1TSHRALDH1A1
SCHEMBL14645853 0.83 GPR35 (0.74) GPR35L3MBTL1NPSR1TSHRMAPT
SCHEMBL14645768 0.83 GPR35 (0.74) GPR35L3MBTL1NPSR1TSHRMAPT
SCHEMBL12374321 0.83 GPR35 (0.74) GPR35L3MBTL1NPSR1TSHRMAPT
SCHEMBL1593215 0.83 GPR35 (0.74) GPR35L3MBTL1NPSR1TSHRMAPT
SCHEMBL18558705 0.82 GPR35 (0.58) GPR35L3MBTL1NPSR1TSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2571888-B1 METHODS OF MAKING FUSED THIOPHENES CORNING INC (US) 2014-12-31 EP disclosed
EP-2571888-A1 METHODS OF MAKING FUSED THIOPHENES Corning Incorporated (US) 2013-03-27 EP disclosed
US-8217183-B2 Methods of making fused thiophenes CORNING INCORPORATED (US) 2012-07-10 US disclosed
WO-2011146308-A1 METHODS OF MAKING FUSED THIOPHENES CORNING INCORPORATED (US) 2011-11-24 WO disclosed
US-20110288306-A1 METHODS OF MAKING FUSED THIOPHENES CORNING INCORPORATED 2011-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288306-A1 METHODS OF MAKING FUSED THIOPHENES DCX, TST, GNPAT GPR35 2757/4885L3MBTL1 3979/4885NPSR1 2637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.